Lot-to-lot consistency, safety, tolerability and immunogenicity of an investigational hexavalent vaccine in US infants

Stanley L. Block, Nicola P. Klein, Kwabena Sarpong, Stephen Russell, John Fling, Maria Petrecz, Sheryl Flores, Jin Xu, Guanghan Liu, Jon E. Stek, Ginamarie Foglia, Andrew W. Lee

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Background: This multicenter phase III study (NCT01340937) evaluated the consistency of immune responses to 3 separate lots of diphtheria-tetanus toxoids-acellular pertussis 5, inactivated poliovirus vaccine, Haemophilus influenzae type b, and hepatitis B (DTaP5-IPV-Hib-HepB), an investigational hexavalent vaccine (HV). Methods: Healthy infants were randomized (2:2:2:1) to receive HV or Pentacel (Control). Groups 1, 2 and 3 received HV at 2, 4 and 6 months, and Control at 15 months. Group 4 received Control at 2, 4, 6 and 15 months, plus Recombivax HB (HepB) at 2 and 6 months. Concomitant Prevnar 13 was given to all groups at 2, 4, 6 and 15 months; pentavalent rotavirus vaccine (RV5) was given to all groups at 2, 4 and 6 months. Blood specimens (3-5 mL) were collected immediately before administration of dose 1, postdose 3, immediately before toddler dose, and after toddler dose. Adverse events were recorded after each vaccination. Results: The 3 manufacturing lots of HV induced consistent antibody responses to all antigens. Immunogenicity of HV was noninferior to Control for all antibodies, except for pertussis filamentous hemagglutinin geometric mean concentration postdose 3, and pertussis pertactin (PRN) geometric mean concentration after toddler dose. Postdose 3 immunogenicity of concomitantly administered Prevnar 13 was generally similar (except for serotype 6B) when given with HV or Control. Adverse events of HV were similar to Control, except for a higher rate of fever ≥38.0°C [49.2% vs. 35.4%, estimated difference 13.7% (8.4, 18.8)]. Conclusions: HV demonstrated lot-to-lot manufacturing consistency; safety and immunogenicity were comparable with the licensed vaccines. HV provides a new combination vaccine option within the US 2-month, 4-month and 6-month vaccine series.

Original languageEnglish (US)
Pages (from-to)202-208
Number of pages7
JournalPediatric Infectious Disease Journal
Issue number2
StatePublished - 2017


  • DTaP
  • Hepatitis B
  • Hexavalent
  • Hib
  • Immunogenicity
  • Lot consistency
  • Polio
  • Safety
  • Vaccine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Lot-to-lot consistency, safety, tolerability and immunogenicity of an investigational hexavalent vaccine in US infants'. Together they form a unique fingerprint.

Cite this